Genmab A (GMAB) Research & Development (2018 - 2026)
Genmab A's (GMAB) quarterly Research & Development came in at -$440.0 million in Q1 2026, down 22.56% YoY from -$568.2 million in Q1 2025, and up 59.26% on a QoQ basis from -$1.1 billion in Q3 2025.
Genmab A (GMAB) Research & Development (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Research & Development data on file, last reported at -$440.0 million in Q1 2026.
- Quarterly Research & Development fell 22.56% year-over-year to -$440.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 7.43% YoY) and the FY2025 annual result came in at $1.6 billion, up 13.58% from the prior year.
- Research & Development climbed to -$440.0 million in Q1 2026, from -$1.1 billion in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$335.0 million in Q1 2024 to a low of -$1.1 billion in Q3 2025.
- A 3-year average of -$666.4 million and a median of -$696.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2025 — Research & Development dropped 3.88% — and 2026, when it retreated 22.56%.
- Tracing GMAB's Research & Development over 3 years: stood at -$1.0 billion in 2024, then slipped by 4.65% to -$1.1 billion in 2025, then surged by 59.26% to -$440.0 million in 2026.
- The last three Research & Development figures came in at -$440.0 million (Q1 2026), -$1.1 billion (Q3 2025), and -$723.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 459.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 459.00 Mn |
| Mar 31, 2026 | -440.00 Mn |
| Sep 30, 2025 | -1.08 Bn |
| Jun 30, 2025 | -723.00 Mn |
| Mar 31, 2025 | -359.00 Mn |
| Sep 30, 2024 | -1.03 Bn |
| Jun 30, 2024 | -696.00 Mn |
| Mar 31, 2024 | -335.00 Mn |
| Sep 30, 2020 | -721.00 |
| Dec 31, 2019 | -608.00 |
| Sep 30, 2019 | -607.89 Mn |
| Dec 31, 2018 | -343.24 Mn |